Assessment of anti-malondialdehyde-acetaldehyde antibody frequencies in rheumatoid arthritis with new data from two independent cohorts, meta-analysis, and meta-regression.

Autor: Rodriguez-Martinez L; Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago (IDIS), Santiago de Compostela, 15706, Spain.; Clinical Pharmacology Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, 15706, Spain., García-Moreno C; Unit of Synthesis and Biomedical Applications of Peptides, Institute of Advanced Chemistry of Catalonia, Consejo Superior de Investigaciones Científicas, (IQAC-CSIC), Barcelona, 08034, Spain., Perez-Pampin E; Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago (IDIS), Santiago de Compostela, 15706, Spain., Gómara MJ; Unit of Synthesis and Biomedical Applications of Peptides, Institute of Advanced Chemistry of Catalonia, Consejo Superior de Investigaciones Científicas, (IQAC-CSIC), Barcelona, 08034, Spain., Sarmiento-Monroy JC; Arthritis Unit, Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain., Lopez-Golán Y; Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago (IDIS), Santiago de Compostela, 15706, Spain., Gómez-Puerta JA; Arthritis Unit, Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain., Mera-Varela A; Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago (IDIS), Santiago de Compostela, 15706, Spain.; Department of Medicine, Faculty of Medicine, Universidade de Santiago de Compostela, Santiago de Compostela, 15705, Spain., Conde C; Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago (IDIS), Santiago de Compostela, 15706, Spain., Sanmartí R; Arthritis Unit, Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain., Haro I; Unit of Synthesis and Biomedical Applications of Peptides, Institute of Advanced Chemistry of Catalonia, Consejo Superior de Investigaciones Científicas, (IQAC-CSIC), Barcelona, 08034, Spain. isabel.haro@iqac.csic.es., González A; Experimental and Observational Rheumatology and Rheumatology Unit, Instituto de Investigacion Sanitaria-Hospital Clínico Universitario de Santiago (IDIS), Santiago de Compostela, 15706, Spain. agmartinezp@ser.es.
Jazyk: angličtina
Zdroj: Arthritis research & therapy [Arthritis Res Ther] 2023 Oct 05; Vol. 25 (1), pp. 192. Date of Electronic Publication: 2023 Oct 05.
DOI: 10.1186/s13075-023-03180-x
Abstrakt: Background: Autoantibodies are critical elements in RA pathogenesis and clinical assessment. The anti-malondialdehyde-acetaldehyde (anti-MAA) antibodies are potentially useful because of their claimed high sensitivity for all RA patients, including those lacking RF and anti-CCP antibodies. Therefore, we aimed to replicate these findings.
Methods: We independently attempted replication in Santiago and Barcelona using sera from 517 and 178 RA patients and 272 and 120 healthy controls, respectively. ELISA protocols for anti-MAA antibodies included five antigens (human serum albumin in three formulations, fibrinogen, and a synthetic peptide) and assays for the IgG, IgM, and IgA isotypes. We integrated our results with information found by searching the Web of Science for reports of anti-MAA antibodies in RA. The available patients (4989 in 11 sets) were included in a meta-analysis aimed at heterogeneity between studies. Factors accounting for heterogeneity were assessed with meta-regression.
Results: The sensitivity of anti-MAA antibodies in our RA patients was low, even in seropositive patients, with the percentage of positives below 23% for all ELISA conditions. Our results and bibliographic research showed IgG anti-MAA positive patients ranging from 6 to 92%. The extreme between-studies heterogeneity could be explained (up to 43%) in univariate analysis by sex, African ethnicity, the site of study, or recruitment from the military. The best model, including African ancestry and smoking, explained a high heterogeneity fraction (74%).
Conclusion: Anti-MAA antibody sensitivity is extremely variable between RA patient collections. A substantial fraction of this variability cannot be attributed to ELISA protocols. On the contrary, heterogeneity is determined by complex factors that include African ethnicity, smoking, and sex.
(© 2023. BioMed Central Ltd., part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: